Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2

AIDS

Volumn 24, Issue 6, 2010, Pages 932-935

  Margolick, Joseph B ^a   Imteyaz, Hejab ^a   Gallant, Joel E ^b   Langan, Susan J ^a   Dinoso, Jason B ^c   Siliciano, Janet ^c   Blankson, Joel ^c   Nilles, Tricia L ^a   Smith, Kendall A ^d   Apuzzo, Linda G ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Division of Infectious Diseases   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; INTERLEUKIN 2; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; CASE REPORT; CD4 LYMPHOCYTE COUNT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; LETTER; MALE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; WESTERN BLOTTING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOTTING, WESTERN; HIV SEROPOSITIVITY; HIV-1; HUMANS; INTERLEUKIN-2; MALE; TREATMENT OUTCOME;

EID: 77949562114     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328333adfb     Document Type: Letter

References (14)

1. Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996; 93:10405-10410.
2. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003; 9:540-547.
3. Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, et al. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIVR patients: a randomized controlled trial. HIV Clin Trials 2000; 1:1-15.
4. Dybul M, Hidalgo B, Chun T-W, Belson M, Migueles SA, Justement JS, et al. Pilot study of the effects of intermittent Interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002; 185:61-68.
5. R cell noncytotoxic anti-HIV response during primary HIV-1 infection. J Clin Immunol 2004; 24:135-144.
6. Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meif-fredy V, Venet A, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses 2007; 23:1105-1113.
7. The INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-1559.
8. Smith KA, Andjelic S, Popmihajlov Z, Kelly-Rossini L, Sass A, Lesser M, et al. Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial. PLoS Clin Trials 2007; 2:e5.
9. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536.
10. Finzi D, Hermankova M, Pierson T, Carruth L, Buck C, Quinn JB, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
11. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cyto-toxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104:6776-6781.
12. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med 2004; 1:137-148.
13. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
14. Prazuck T, Lafeuillade A, Hocqueloux L, Viard J-P, Avettand- Fèoël V, Rouzioux C. Can HAART initiation at early acute HIV infection benefit the immune-virology outcome despite subsequent treatment cessation? [Abstract #695 2008]. Conference on Retroviruses and Opportunistic Infections; Boston, Massachusetts, USA; 2008.